


The rate of cases turning to severe


- The Rate of Patients with Clinical Deterioration and Duration of Hospitalization in the Treatment Group and Control Group
- In Kan Jang[®], Group A of 68 patients, 12 were dropouts, and three were withdrawn from the study due to lack of efficacy and disease progression; they continued the treatment with steroids and antibiotics. Figure 1.
- In Placebo Group B, of 72 patients, 16 were dropouts, and ten were withdrawn from the study due to lack of efficacy and disease progression; they continued the treatment with steroids and antibiotics. Figure 1.
- Therefore:
 - Group A's (Kan Jang, 56 patients) disease progression rate (5.36%).
 - Group B's (placebo, 56 patients) disease progression rate (17.86%).
- Where $p = 0.0176$ (significant result) at 95% significance level (Confidence 95%), power 90.15%.
- Absolute risk reduction by Kan Jang treatment is 12.5% ($ARR=0.125$),
- Relative risk/odds ratio = 0.3
- Relative risk reduction ($RRR, \%$) = 70 %.
- The number of patients required to treat with Kan Jang to prevent one additional bad outcome (defined as the Number Needed to Treat, $NNT = 1/ARR = 8$) comprises 8.
- The higher ARR and lower NNT are, the more effective the intervention is.
- [Relative risk, relative and absolute risk reduction, number needed to treat and confidence intervals - Smart Health Choices - NCBI Bookshelf \(nih.gov\)](#)

The rate of cases turning to severe




Comparison of Survival Curves		
Log-rank (Mantel-Cox) test		
Chi square	4,648	
df	1	
P value	0,0311	
P value summary	*	
Are the survival curves sig different?	Yes	
Gehan-Breslow-Wilcoxon test		
Chi square	5,112	
df	1	
P value	0,0238	
P value summary	*	
Are the survival curves sig different?	Yes	
Median survival		
Kan Jang, n=34	Undefined	
Placebo, n=52	Undefined	
Hazard Ratio (Mantel-Haenszel)		
Ratio (and its reciprocal)	A/B	B/A
95% CI of ratio	0,2906	3,441
	0,09448 to 0,8938	1,119 to 10,58
Hazard Ratio (logrank)		
Ratio (and its reciprocal)	A/B	B/A
95% CI of ratio	0,2768	3,612
	0,09789 to 0,8627	1,159 to 10,22 ₂

The rate of cases turning to severe, PPA



The rate of cases turning to severe, ITT analysis




The overall clinical effectiveness defined as the ratio of effective to ineffective cases vs placebo control


- Group A (Kan Jang, 56 patients) disease progression rate (5.36%).
- Group B's (placebo, 56 patients) disease progression rate (17.86%).
- Group A: Absolute effectiveness - 94,56%
 - Within group ratio of effective to ineffective cases 17.65
- Group B: Absolute effectiveness - 82,14%
- Relative effectiveness 4.6
 - Within group ratio of effective to ineffective cases 4.6
- Overall clinical effectiveness vs placebo control = 3.84
- [A/B-Test Calculator - Power & Significance - ABTestGuide.com](https://www.abtestguide.com/ab-test-calculator/)

Days at clinic or home



ITT analysis in 140 patients



PP analysis in 100 patients




Days at clinic or home



Days elapsed	Kan Jang, n=68		Placebo, n=72	
	%	SEM	%	SEM
0	100		100	
2			100	
3			100	
4			100	
5	100		100	
7	97,0	2,1	98,5	1,5
8	88,4	4,2	94,7	3,0
9	74,2	5,8	85,0	4,9
10	60,1	6,5	65,2	6,6
11	44,2	6,6	61,2	6,8
12	37,1	6,4	55,0	7,0
13	37,1		50,8	7,1
14	20,4	5,4	27,7	6,6
15	17,9	5,3	20,8	6,1
16	15,3	5,1	13,9	5,2
17	12,8	4,9		
18			11,5	4,8
19			9,2	4,4
21	0	0	0	0
Median at clinic /home				
Kan Jang, n=68		11		
Placebo, n=72		14		
Ratio (and its reciprocal)		0,7857	1,273	
95% CI of ratio		0,5305 to 1,164	0,8594 to 1,885	
Hazard Ratio (Mantel-Haenszel)		A/B	B/A	
Ratio (and its reciprocal)		1,232	0,8117	
95% CI of ratio		0,7780 to 1,951	0,5126 to 1,285	


Negative conversion rate of SARS CoV-2 virus detection

ITT analysis in 140 patients






Hazard Ratio, Kan Jang/Placebo - 1,69
95% CI of ratio: from 0,8698 to

Days elapsed	Kan Jang, n=68		Placebo, n=72	
		SEM		SEM
0	100		100	
7	89,6	3,7	88,9	3,7
14	19,3	5,2	36,3	6,4
21	0	0	0	0




Disappearance rate of symptoms Cough



ITT analysis in 140 patients

Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	0,045	0,025	67	0,085	0,044	71
5	0,030	0,052	67	-0,045	0,050	66
7	-0,169	0,073	59	-0,033	0,075	60
9	-0,436	0,072	55	-0,333	0,067	51
11	-0,509	0,082	55	-0,412	0,075	51
14	-0,815	0,121	54	-0,574	0,113	47
21	-1,057	0,138	53	-0,766	0,137	47


Cough



PP analysis in 100 patients

Days	Kan Jang, n = 53			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
3	0,038	0,026	53	0,000	0,030	47
5	0,038	0,054	53	-0,021	0,037	47
7	-0,226	0,069	53	-0,128	0,049	47
9	-0,453	0,074	53	-0,340	0,070	47
11	-0,528	0,083	53	-0,426	0,079	47
14	-0,830	0,123	53	-0,574	0,113	47
21	-1,057	0,138	53	-0,766	0,137	47


Cough



ITT analysis in a subgroup of 54 patients

Days	Kan Jang, n = 34			Placebo, n=20		
	Mean	SD	n	Mean	SD	n
1	0	0	34	0	0	20
3	0	0	34	0	0	20
5	-0,088	0,049	34	-0,150	0,082	20
7	-0,407	0,096	27	-0,133	0,091	15
9	-0,815	0,076	27	-0,667	0,126	15
11	-0,889	0,097	27	-0,667	0,126	15
14	-1,370	0,152	27	-1,067	0,228	15
21	-1,667	0,151	27	-1,333	0,252	15

Cough





PP analysis in a subgroup of 42 patients


Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	27	0	0	15
3	0	0	27	0	0	15
5	-0,037	0,037	27	0	0	15
7	-0,407	0,096	27	-0,133	0,091	15
9	-0,815	0,076	27	-0,667	0,126	15
11	-0,889	0,097	27	-0,667	0,126	15
14	-1,370	0,152	27	-1,067	0,228	15
21	-1,667	0,151	27	-1,333	0,252	15

Sore throat pain

ITT analysis in 140 patients




Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	-0,030	0,030	67	-0,04	0,03	71
5	-0,403	0,067	67	-0,36	0,07	66
7	-0,763	0,101	59	-0,52	0,09	60
9	-1,000	0,108	56	-0,83	0,12	52
11	-1,179	0,117	56	-0,88	0,12	52
14	-1,218	0,118	55	-0,98	0,13	49
21	-1,296	0,120	54	-1,08	0,14	49



Days elapsed	Kan Jang, n=68		Placebo, n=72	
0	100		100	
1	100			
5	89,583	4,409	86,111	5,764
7	57,589	7,204	66,019	7,984
9	33,341	7,743	38,221	8,791
11	9,093	4,950	24,323	7,876
14	3,031	2,974	4,054	3,926
21	0	0	0	0


Sore throat pain

PP analysis in 103 patients



Days	Kan Jang, n = 54			Placebo, n=49		
	Mean	SD	n	Mean	SD	n
1	0	0	54	0	0	49
3	-0,019	0,032	54	-0,04	0,04	49
5	-0,370	0,071	54	-0,41	0,08	49
7	-0,815	0,106	54	-0,61	0,10	49
9	-1,037	0,109	54	-0,86	0,12	49
11	-1,222	0,117	54	-0,92	0,13	49
14	-1,241	0,118	54	-0,98	0,13	49
21	-1,296	0,120	54	-1,08	0,14	49


Sore throat pain



ITT analysis in a subgroup of 54 patients

Days	Kan Jang, n = 34			Placebo, n=20		
	Mean	SD	n	Mean	SD	n
1	0	0	34	0	0	20
3	-0,059	0,041	34	-0,150	0,082	20
5	-0,706	0,099	34	-1,000	0,103	20
7	-1,259	0,137	27	-1,333	0,126	15
9	-1,481	0,135	27	-1,800	0,107	15
11	-1,741	0,126	27	-1,933	0,067	15
14	-1,741	0,126	27	-1,933	0,067	15
21	-1,778	0,123	27	-1,933	0,067	15




Sore throat pain



PP analysis in a subgroup of 42 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	27	0	0	15
3	0	0	27	0	0	15
5	-0,037	0,037	27	0	0	15
7	-0,407	0,096	27	-0,133	0,091	15
9	-0,815	0,076	27	-0,667	0,126	15
11	-0,889	0,097	27	-0,667	0,126	15
14	-1,370	0,152	27	-1,067	0,228	15
21	-1,667	0,151	27	-1,333	0,252	15


Runny nose



ITT analysis in 140 patients

Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	0,015	0,034	67	-0,028	0,020	71
5	-0,149	0,057	67	-0,121	0,040	66
7	-0,237	0,065	59	-0,217	0,059	60
9	-0,436	0,096	55	-0,314	0,091	51
11	-0,582	0,124	55	-0,333	0,096	51
14	-0,611	0,128	54	-0,383	0,108	47
21	-0,660	0,135	53	-0,426	0,113	47


Runny nose PP analysis in 100 patients



PP analysis in 100 patients

Days	Kan Jang, n = 53			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
3	-0,019	0,019	53	-0,021	0,021	47
5	-0,151	0,050	53	-0,128	0,049	47
7	-0,283	0,068	53	-0,213	0,060	47
9	-0,453	0,099	53	-0,340	0,098	47
11	-0,604	0,127	53	-0,362	0,103	47
14	-0,623	0,130	53	-0,383	0,108	47
21	-0,660	0,135	53	-0,426	0,113	47


Runny nose



ITT analysis in a subgroup of 54 patients

Days	Kan Jang, n = 34			Placebo, n=20		
	Mean	SD	n	Mean	SD	n
1	0	0	34	0	0	20
3	-0,029	0,029	34,000	-0,050	0,050	20
5	-0,235	0,074	34,000	-0,300	0,105	20
7	-0,407	0,110	27,000	-0,533	0,133	15
9	-0,630	0,161	27,000	-0,800	0,223	15
11	-0,889	0,209	27,000	-0,867	0,236	15
14	-0,926	0,213	27,000	-0,933	0,248	15
21	-0,926	0,213	27,000	-0,933	0,248	15




Runny nose



PP analysis in a subgroup of 42 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	27	0	0	15
3	-0,037	0,037	27	-0,067	0,067	15
5	-0,148	0,070	27	-0,333	0,126	15
7	-0,407	0,110	27	-0,533	0,133	15
9	-0,630	0,161	27	-0,800	0,223	15
11	-0,889	0,209	27	-0,867	0,236	15
14	-0,926	0,213	27	-0,933	0,248	15
21	-0,926	0,213	27	-0,933	0,248	15


Muscle soreness



ITT analysis in 140 patients

Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0,000	0,000	68	0	0	72
3	-0,104	0,048	67	-0,056	0,044	71
5	-0,463	0,100	67	-0,197	0,087	66
7	-0,661	0,136	59	-0,383	0,107	60
9	-0,873	0,142	55	-0,647	0,122	51
11	-0,927	0,142	55	-0,667	0,121	51
14	-1,000	0,145	54	-0,723	0,132	47
21	-1,019	0,149	53	-0,723	0,132	47


Muscle soreness



PP analysis in 100 patients

Days	Kan Jang, n = 53			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
3	-0,094	0,049	53	-0,128	0,058	47
5	-0,472	0,103	53	-0,277	0,090	47
7	-0,792	0,138	53	-0,532	0,117	47
9	-0,906	0,146	53	-0,660	0,130	47
11	-0,943	0,146	53	-0,681	0,129	47
14	-1,000	0,148	53	-0,723	0,132	47
21	-1,019	0,149	53	-0,723	0,132	47


Muscle soreness



ITT analysis in a subgroup of 54 patients

Days	Kan Jang, n = 34			Placebo, n=20		
	Mean	SD	n	Mean	SD	n
1	0	0	34	0	0	20
3	-0,029	0,029	34,000	-0,050	0,050	20
5	-0,235	0,074	34,000	-0,300	0,105	20
7	-0,407	0,110	27,000	-0,533	0,133	15
9	-0,630	0,161	27,000	-0,800	0,223	15
11	-0,889	0,209	27,000	-0,867	0,236	15
14	-0,926	0,213	27,000	-0,933	0,248	15
21	-0,926	0,213	27,000	-0,933	0,248	15

Muscle soreness




PP analysis in a subgroup of 42 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	27	0	0	15
3	-0,222	0,082	27	-0,400	0,131	15
5	-0,815	0,169	27	-0,800	0,200	15
7	-1,259	0,217	27	-1,200	0,262	15
9	-1,407	0,222	27	-1,400	0,273	15
11	-1,407	0,222	27	-1,400	0,273	15
14	-1,407	0,222	27	-1,400	0,273	15
21	-1,444	0,222	27	-1,400	0,273	15


Fatigue

ITT analysis in 140 patients



Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	-0,015	0,045	67	-0,042	0,055	71
5	-0,284	0,082	67	-0,348	0,079	66
7	-0,729	0,123	59	-0,567	0,112	60
9	-1,145	0,088	55	-1,196	0,105	51
11	-1,273	0,088	55	-1,353	0,104	51
14	-1,481	0,083	54	-1,447	0,105	47
21	-1,792	0,056	53	-1,681	0,092	47


Fatigue



PP analysis in 100 patients

Days	Kan Jang, n = 53			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
3	0,019	0,043	53	-0,128	0,065	47
5	-0,189	0,076	53	-0,383	0,089	47
7	-0,830	0,117	53	-0,745	0,103	47
9	-1,151	0,091	53	-1,191	0,112	47
11	-1,264	0,090	53	-1,340	0,111	47
14	-1,491	0,084	53	-1,447	0,105	47
21	-1,792	0,056	53	-1,681	0,092	47


Fatigue



ITT analysis in a subgroup of 54 patients

Days	Kan Jang, n = 34			Placebo, n=20		
	Mean	SD	n	Mean	SD	n
1	0	0	34	0	0	20
3	-0,147	0,062	34	-0,4	0,11239	20
5	-0,588	0,120	34	-0,85	0,109424	20
7	-1,111	0,123	27	-1,26667	0,153271	15
9	-1,333	0,092	27	-1,4	0,213809	15
11	-1,519	0,098	27	-1,66667	0,186871	15
14	-1,778	0,082	27	-1,73333	0,181703	15
21	-1,926	0,051	27	-1,93333	0,153271	15



Fatigue



PP analysis in a subgroup of 42 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	27	0	0	15
3	-0,07	0,05	27	-0,47	0,13	15
5	-0,41	0,11	27	-0,80	0,14	15
7	-1,11	0,12	27	-1,27	0,15	15
9	-1,33	0,09	27	-1,40	0,21	15
11	-1,52	0,10	27	-1,67	0,19	15
14	-1,78	0,08	27	-1,73	0,18	15
21	-1,93	0,05	27	-1,93	0,15	15

Headache




ITT analysis in 140 patients

Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	-0,119	0,050	67	-0,028	0,049	71
5	-0,493	0,091	67	-0,439	0,087	66
7	-0,864	0,112	59	-0,683	0,105	60
9	-1,200	0,102	55	-1,157	0,110	51
11	-1,491	0,097	55	-1,392	0,109	51
14	-1,574	0,094	54	-1,511	0,100	47
21	-1,736	0,086	53	-1,638	0,103	47

Headache


PP analysis in 100 patients



Days	Kan Jang, n = 53			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
3	-0,094	0,049	53	-0,085	0,051	47
5	-0,434	0,091	53	-0,489	0,096	47
7	-0,962	0,111	53	-0,830	0,102	47
9	-1,226	0,103	53	-1,149	0,114	47
11	-1,491	0,099	53	-1,383	0,112	47
14	-1,585	0,095	53	-1,511	0,100	47
21	-1,736	0,086	53	-1,638	0,103	47


Headache

ITT analysis in a subgroup of 54 patients



Days	Kan Jang, n = 34			Placebo, n=20		
	Mean	SD	n	Mean	SD	n
1	0	0	34	0	0	20
3	-0,235	0,074	34	-0,350	0,109	20
5	-0,794	0,132	34	-1,050	0,153	20
7	-1,259	0,126	27	-1,467	0,133	15
9	-1,519	0,124	27	-1,667	0,126	15
11	-1,852	0,103	27	-1,933	0,067	15
14	-1,926	0,091	27	-1,933	0,067	15
21	-1,926	0,091	27	-1,933	0,067	15


Headache



PP analysis in a subgroup of 42 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	27	0	0	15
3	-0,148	0,070	27	-0,333	0,126	15
5	-0,630	0,132	27	-0,933	0,182	15
7	-1,259	0,126	27	-1,467	0,133	15
9	-1,519	0,124	27	-1,667	0,126	15
11	-1,852	0,103	27	-1,933	0,067	15
14	-1,926	0,091	27	-1,933	0,067	15
21	-1,926	0,091	27	-1,933	0,067	15


Loss of taste




ITT analysis in 140 patients

Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	0	0	67	0	0	71
5	0	0	67	0	0	66
7	0	0	59	0	0	60
9	0	0	55	-0,019	0,019	52
11	-0,036	0,025	55	-0,038	0,027	52
14	-0,074	0,036	54	-0,063	0,046	48
21	-0,094	0,049	53	-0,063	0,046	48

Change from baseline, Day X - Day 1




Loss of taste



PP analysis in 101 patients

Days	Kan Jang, n = 53			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	48
3	0	0	53	0	0	48
5	0	0	53	0	0	48
7	0	0	53	0	0	48
9	0	0	53	-0,021	0,021	48
11	-0,038	0,026	53	-0,042	0,029	48
14	-0,075	0,037	53	-0,063	0,046	48
21	-0,094	0,049	53	-0,063	0,046	48

Loss of taste




ITT analysis in a subgroup of 54 patients

Days	Kan Jang, n = 34			Placebo, n=20		
	Mean	SD	n	Mean	SD	n
1	0	0	34	0	0	20
3	0	0	34	0	0	20
5	0	0	34	0	0	20
7	0	0	27	0	0	15
9	0	0	27	-0,067	0,067	15
11	-0,074	0,051	27	-0,133	0,091	15
14	-0,148	0,070	27	-0,200	0,145	15
21	-0,185	0,093	27	-0,200	0,145	15

Loss of taste




Change from baseline, Day X - Day 1



PP analysis in a subgroup of 42 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	27	0	0	15
3	0	0	27	0	0	15
5	0	0	27	0	0	15
7	0	0	27	0	0	15
9	0	0	27	-0,067	0,067	15
11	-0,074	0,051	27	-0,133	0,091	15
14	-0,148	0,070	27	-0,200	0,145	15
21	-0,185	0,093	27	-0,200	0,145	15


Loss of smell



ITT analysis in 140 patients

Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	0	0	67	-0,01	0,01	71
5	-0,03	0,02	67	-0,06	0,04	66
7	-0,05	0,03	59	-0,08	0,04	60
9	-0,07	0,04	55	-0,13	0,06	52
11	-0,11	0,06	55	-0,19	0,07	52
14	-0,09	0,05	54	-0,19	0,06	48
21	-0,11	0,06	53	-0,25	0,08	48


Loss of smell



PP analysis in 101 patients

Days	Kan Jang, n = 53			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	48
3	0	0	53	0	0	48
5	-0,019	0,019	53	-0,042	0,042	48
7	-0,038	0,026	53	-0,063	0,046	48
9	-0,057	0,032	53	-0,104	0,054	48
11	-0,075	0,045	53	-0,167	0,062	48
14	-0,094	0,049	53	-0,188	0,064	48
21	-0,113	0,058	53	-0,250	0,082	48

Loss of smell




ITT analysis in a subgroup of 54 patients

Days	Kan Jang, n = 34			Placebo, n=20		
	Mean	SD	n	Mean	SD	n
1	0	0	34	0	0	20
3	0	0	34	0	0	20
5	-0,029	0,029	34	-0,150	0,109	20
7	-0,037	0,037	27	-0,133	0,133	15
9	-0,074	0,051	27	-0,267	0,153	15
11	-0,111	0,082	27	-0,400	0,163	15
14	-0,148	0,088	27	-0,467	0,165	15
21	-0,148	0,088	27	-0,533	0,192	15

Loss of smell

change from baseline, Day X - Day 1




PP analysis in a subgroup of 45 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	30	0	0	15
3	0	0	30	0	0	15
5	-0,033	0,033	30	-0,13	0,13	15
7	-0,033	0,033	30	-0,13	0,13	15
9	-0,067	0,046	30	-0,27	0,15	15
11	-0,100	0,074	30	-0,40	0,16	15
14	-0,133	0,079	30	-0,47	0,17	15
21	-0,133	0,079	30	-0,53	0,19	15


Physical activity

ITT analysis in 140 patients



Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
7	1,373	0,239	59	0,617	0,341	60
14	4,333	0,254	54	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47

PP analysis in 100 patients



Days	Kan Jang, n = 51			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
7	1,642	0,217	53	1,255	0,231	47
14	4,377	0,254	53	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47



Workout

ITT analysis in 140 patients

Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
7	5,254	1,124	59	1,333	1,411	60
14	12,315	0,733	54	10,426	1,052	47
21	19,434	0,837	53	17,340	1,234	47

PP analysis in 100 patients

Days	Kan Jang, n = 53			Placebo, n=47		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
7	1,642	0,217	53	1,255	0,231	47
14	4,377	0,254	53	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47




Cognitive performance

ITT analysis in 140 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
7	4,642	3,622	59	5,269	1,481	60
14	8,758	3,201	55	11,227	1,966	47
21	11,305	3,286	54	13,201	2,026	47

PP analysis in 100 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
7	1,642	0,217	53	1,255	0,231	47
14	4,377	0,254	53	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47





Respiratory symptoms

ITT analysis in 140 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	-1,716	0,369	67	-1,141	0,446	71
7	-7,983	0,900	59	-6,417	0,937	60
14	-15,963	0,936	54	-14,348	0,923	46

PP analysis in 100 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	54	0	0	46
3	-1,500	0,358	54	-1,696	0,480	46
7	-8,815	0,864	54	-7,783	0,890	46
14	-15,963	0,936	54	-14,348	0,923	46





Respiratory symptoms

ITT analysis in a subgroup of 54 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
7	1,373	0,239	59	0,617	0,341	60
14	4,333	0,254	54	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47


PP analysis in in a subgroup of 42 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
7	1,642	0,217	53	1,255	0,231	47
14	4,377	0,254	53	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47



Quality of life

ITT analysis in 140 patients



Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
7	1,373	0,239	59	0,617	0,341	60
14	4,333	0,254	54	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47

PP analysis in 100 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
7	1,642	0,217	53	1,255	0,231	47
14	4,377	0,254	53	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47

Inflammatory marker IL-6


ITT analysis in 140 patients

Days	Kan Jang, n = 68			Placebo, n=72		
	Mean	SD	n	Mean	SD	n
1	12,60	54,29	68	9,39	17,86	72
3	5,59	9,87	66	7,39	12,83	71
7	4,88	7,09	59	6,57	12,77	60
14	2,37	2,60	54	2,84	5,01	47


ITT analysis in 140 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
3	-7,235	6,788	66	-0,554	0,970	70
7	-8,702	7,471	59	-0,103	2,131	60
14	-11,575	8,257	54	-2,646	1,037	47

Blood cytokine IL-6



Cytokine IL-6




Inflammatory marker IL-6

PP analysis in 100 patients

Days	Kan Jang, n = 54			Placebo, n=46		
	Mean	SD	n	Mean	SD	n
1	0	0	54	0	0	46
3	-9,238	8,243	54	-1,712	0,536	46
7	-10,677	8,101	54	-1,168	1,206	46
14	-11,575	8,257	54	-2,229	0,970	46


PP analysis in a subgroup of 42 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	27	0	0	15
3	-2,194	0,701	27	-1,711	0,707	15
7	-3,323	0,939	27	-1,758	0,736	15
14	-4,038	1,201	27	-1,758	0,736	15



Inflammatory marker D-dimer

ITT analysis in 140 patients




Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
7	1,373	0,239	59	0,617	0,341	60
14	4,333	0,254	54	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47

PP analysis in 59 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
7	1,642	0,217	53	1,255	0,231	47
14	4,377	0,254	53	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47

Inflammatory marker C-reactive protein



ITT analysis in 140 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
7	1,373	0,239	59	0,617	0,341	60
14	4,333	0,254	54	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47

PP analysis in 100 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
7	1,642	0,217	53	1,255	0,231	47
14	4,377	0,254	53	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47



Body temperature

ITT analysis in 140 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	68	0	0	72
7	1,373	0,239	59	0,617	0,341	60
14	4,333	0,254	54	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47


PP analysis in 99 patients

Days	Kan Jang, n = 27			Placebo, n=15		
	Mean	SD	n	Mean	SD	n
1	0	0	53	0	0	47
7	1,642	0,217	53	1,255	0,231	47
14	4,377	0,254	53	3,511	0,467	47
21	5,830	0,343	53	4,872	0,523	47



Body temperature

Patients with body temperature



Time to fever resolution

Days elapsed	Kan Jang, n=68		Placebo, n=72	
0	100		100	
1	98,529	1,460	97,222	1,937
3	98,529		91,586	3,288
5	67,739	5,796	78,073	5,015
7	29,527	5,943	46,844	6,447
9	17,716	5,164	22,307	5,957
11	8,858	5,127	0,000	0,000
14	0	0		

Is your test result significant? Does it have enough power?

Play with the controls and get a better feel for how a lower confidence level will boost the power or how an increase in test size can make a small CR-difference significant

Pre-test calculation or post-test evaluation?

☐ Pre-test analysis

☒ Test evaluation

Test data

Visitors A: 68 Conversions A: 39

Visitors B: 72 Conversions B: 45

Apply changes

Settings

Hypothesis H_0

☒ One-sided


☐ Two-sided



Confidence $1-\alpha$


☐ 90%

☒ 95%

☐ 99%










Conditional “biological signatures” of Andrographis, Eleutherococcus and their combination Kan Jang

The color-coded heat-maps identify **diseases and functions** that are expected to **increase** or **decrease**.



- Diseases or Functions**
- antigen presentation
 - clearance of virus
 - antiviral response of myeloid cells
 - emotional behavior
 - locomotion
 - active avoidance response
 - sexual receptivity
 - aggressive behavior
 - appetite, etc.



Direct antiviral effect

- Effects on viral life cycle in infected host cells – targets preventing the virus RNA synthesis and replication
- inhibiting virus structural proteins
- Viricidal effects

Anti-inflammatory activity

- Inhibition of NFkB mediated signaling
- Inhibition of PLA2, arachidonic acid release and metabolism
- Inhibition of nitric oxide generation

Andrographis Eleutherococcus

Modulation of the immune response

- Increased expression of defensins peptides,
- Increased expression of pathogen pattern recognition proteins - TLRs,
- Increased expression of interferons,
- Inhibition of IL-6, IL-1 β , IL-10, TNF release,
- Inhibition of NFkB
- Activation natural killer cells,
- Activation of phagocytosing cells,
- Activation of T- and B - lymphocytes
- Activation of melatonin signaling

Detoxification and reparation of oxidative stress induced damages in compromised cells

- Activation of NRF2-signaling pathway proteins (KEAP1)
- Production of Phases I,II metabolizing and antioxidant enzymes : glutathione S-transferase (GST), NAD(P)H quinone oxidoreductase 1 (NQO1) , superoxide dismutase (SOD), and heme oxygenase 1 (HO1).
- Molecular chaperons Hsp70 mediated cytoprotecting, and repairing processes
- Activation of melatonin signaling pathway

Eleutherococcus senticosus
(Rupr. and Maxim.) Maxim.



Andrographis paniculata
(Burm. f.) Nees

Placebo.









100 patients
Completed study

The overall clinical effectiveness:
Kan Jang : Placebo = 3.84

Number patients
needed to treat = 8

140 patients
randomly allocated
to Kan Jang or
placebo

Randomization
masking/blinding



Summary of the results

Kan Jang significantly ameliorates the overall recovery rate by decreasing the following:

- the rate of cases turning to severe,
- negative conversion rate of SARS CoV-2 virus detection.

That is accompanied with decreasing the duration of sick days at the clinic or home compared with the placebo group.

Disappearance rate of inflammatory symptom in the Kan Jang group was significantly improved compared with the placebo group, including:

Beneficial effect of Kan Jang	<ul style="list-style-type: none">• Severity of Respiratory symptoms - Wisconsin URS score• Severity of Cough• Severity of Sore throat pain• Severity of Runny nose• Severity of Muscle soreness• Loss of smell• Physical activity• Workout	No effect on	<ul style="list-style-type: none">• cognitive functions (attention and memory)• quality of life score• inflammatory markers D-dimer and c reactive protein• time to normalization of body temperature
	<ul style="list-style-type: none">• IL6 - only in the subgroup of 86 patients with moderate symptoms, but the effect was statistically insignificant in the sample size of 140 patients with mild to moderate symptoms of COVID-19		<ul style="list-style-type: none">• severity of Fatigue• severity of Headache